Ftse Mib
34.151,41
-0,27%
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
61.194,80
-1,83%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Instill Bio Inc (TIL) Instill Bio Inc (TIL) Notizie

TIL

Instill Bio (TIL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TIL
DataOraFonteTitoloSimboloCompagnia
21/03/202422:00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
14/02/202422:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TILInstill Bio Inc
13/02/202423:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TILInstill Bio Inc
16/01/202414:00GlobeNewswire Inc.Instil Bio Announces Strategic UpdateNASDAQ:TILInstill Bio Inc
05/12/202323:00GlobeNewswire Inc.Instil Bio Announces Effective Date of 1-for-20 Reverse Stock SplitNASDAQ:TILInstill Bio Inc
13/11/202323:27Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TILInstill Bio Inc
13/11/202323:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TILInstill Bio Inc
13/11/202323:00GlobeNewswire Inc.Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
06/11/202313:00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual MeetingNASDAQ:TILInstill Bio Inc
14/08/202313:00GlobeNewswire Inc.Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
26/06/202322:38GlobeNewswire Inc.Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferenceNASDAQ:TILInstill Bio Inc
26/06/202322:33Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TILInstill Bio Inc
11/05/202313:00GlobeNewswire Inc.Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
28/04/202322:37Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:TILInstill Bio Inc
24/04/202322:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TILInstill Bio Inc
10/04/202315:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TILInstill Bio Inc
31/03/202313:40Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TILInstill Bio Inc
31/03/202313:00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
31/01/202323:00GlobeNewswire Inc.Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteNASDAQ:TILInstill Bio Inc
20/01/202322:13Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:TILInstill Bio Inc
20/01/202322:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TILInstill Bio Inc
09/01/202313:00GlobeNewswire Inc.Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerNASDAQ:TILInstill Bio Inc
12/12/202217:45Business WireNewman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)NASDAQ:TILInstill Bio Inc
08/12/202213:00GlobeNewswire Inc.Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in WorkforceNASDAQ:TILInstill Bio Inc
14/11/202222:07GlobeNewswire Inc.Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
08/11/202213:00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TILInstill Bio Inc
31/10/202214:14TipRanksInstil Bio Pauses Clinical Trial EnrollmentsNASDAQ:TILInstill Bio Inc
31/10/202212:00GlobeNewswire Inc.Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to ManufacturingNASDAQ:TILInstill Bio Inc
18/10/202213:00GlobeNewswire Inc.Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung CancerNASDAQ:TILInstill Bio Inc
19/09/202213:20GlobeNewswire Inc.Instil Bio to Present at Jefferies Cell and Genetic Medicine SummitNASDAQ:TILInstill Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TIL

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
CPR
Davide Campari
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
FBK
Finecobank
BIT
TRN
Terna Trasmissione Elett...
BIT
IRE
Iren
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network